The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants
Leila-Sophie Otten, PharmD, Radboud University Medical Centre, Radboud University Nijmegen, Netherlands, provides an overview on an exploration into the practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants. In this study, five anticoagulants (apixaban, edoxaban, betrixaban, rivaroxaban and abigatran) and all 20 small molecule inhibitors were reviewed for possible drug-drug interactions. Half of the combinations were found to result in relevant drug-drug interactions. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
